About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
NKTR - Nektar Therapeutics| Previous Close | $17.22 | Open | $17.36 |
| Volume | 951.1K | Market Cap | 3.046B |
| Yield | Last Dividend |
| Insider Selling: Nektar Therapeutics (NA... | 12/18/20 |
| Nektar Therapeutics (NASDAQ:NKTR) Director Curet Myriam sold 1,560 shares of Nektar Therapeutics stock in a transaction on Tuesday, December 15th. The... | |
| The Week Ahead In Biotech: Supernus, San... | 11/08/20 |
| Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of gua... | |
| Nektar Therapeutics EPS beats by $0.16, ... | 11/05/20 |
| Nektar Therapeutics (NASDAQ:NKTR): Q3 GAAP EPS of -$0.61 beats by $0.16. Revenue of $30M (+2.7% Y/Y) beats by $7.18M.Revenue was higher due to the rec... | |
| Growing M&A momentum drives gains in Rhe... | 10/12/20 |
| Growing M&A momentum drives gains in Rhenman???s flagship healthcare hedge fund Submitted By Hugh Leask | 12/10/2020 - 12:36pm A pick-up in M&A activi... | |
| This Is What Hedge Funds Bought And Sold... | 08/16/20 |
| This Is What Hedge Funds Bought And Sold In The Second Quarter Tyler Durden Sun, 08/16/2020 - 13:00 In addition to the widely publicized changes in Be... | |
| Why Is Nektar (NKTR) Up 12% Since Last E... | 06/06/20 |
| Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Nektar Therapeutics (NKTR) Q1 2020 Earni... | 05/08/20 |
| NKTR earnings call for the period ending March 31, 2020. | |
| Cerus Corporation Announces Strategic Or... | 03/02/20 |
| Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promo... | |
| Analysts Estimate Nektar Therapeutics (N... | 02/20/20 |
| Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with th... | |
| Nektar Therapeutics (NKTR) Stock Sinks A... | 02/06/20 |
| Nektar Therapeutics (NKTR) closed at $22.81 in the latest trading session, marking a -0.52% move from the prior day. | |
| Nektar Therapeutics Pullback May Be Shor... | 01/23/20 |
| Nektar has struggled to gain momentum since its early August sell-off | |
| Why This Opioid Painkiller Is Killing Ne... | 01/15/20 |
| No summary available. | |
| Nektar Slumps As FDA Panel Gives Thumbs ... | 01/15/20 |
| Shares of midcap biopharma Nektar Therapeutics (NASDAQ: NKTR ) are retreating sharply following a negative verdict handed down by FDA staffers for its... | |
| Nektar stock drops more than 10% as FDA ... | 01/14/20 |
| Nektar Therapeutics [sL nktr] shares fell in the extended session Tuesday following a report that a Food and Drug Administration advisory panel voted ... | |
| Stocks making the biggest moves after th... | 01/14/20 |
| Check out the companies making headlines after the bell. | |
| NIO : Thinking about buying stock in Bil... | 01/13/20 |
| NEW YORK, Jan. 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BILI, MSFT, NIO, NKTR, and NVDA. To see how InvestorsO... | |
| The Week Ahead In Biotech: JPMorgan Heal... | 01/12/20 |
| Activity in the biotech space is likely to pick up this week. Events are likely to be headlined by the annual JPMorgan Healthcare Conference. Biotech ... | |
| Shareholder Alert: Robbins LLP Reminds I... | 01/10/20 |
| SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)---- $NKTR #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that purchasers of Nektar... | |
| Nektar Therapeutics Options Pop as Stock... | 01/10/20 |
| Nektar and Bristol-Myers Squibb will expand an ongoing late-stage collaborative trial | |
| Nektar Therapeutics and Bristol-Myers Sq... | 01/10/20 |
| Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab) | |
| Cancer Treatment Centers of America Cont... | 12/05/19 |
| PHOENIX, Dec. 5, 2019 /PRNewswire/ -- Clinical investigators at Cancer Treatment Centers of America?? (CTCA) in Phoenix have dosed the first patient i... | |
| Nektar Therapeutics (NASDAQ:NKTR) Price ... | 11/16/19 |
| Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by Canaccord Genuity from $20.00 to $24.00 in a research report sent to investors on Tue... | |
| Nektar Therapeutics Stock Is Rising on T... | 11/11/19 |
| Nektar Therapeutics released clinical data that raised hope about a drug-development program that has encountered manufacturing problems. | |
| Nektar (NKTR) Q3 Earnings & Revenues Top... | 11/07/19 |
| Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for i... | |
| Nektar Therapeutics (NKTR) Expected to B... | 10/30/19 |
| Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key ... | |
| Nektar's Shares Drop on Rating Downgrade... | 10/09/19 |
| Nektar (NKTR) continues its downfall in 2019. Goldman Sachs downgrades the company's rating from Buy to Sell. | |
| Nektar Hit With Double Downgrade From Go... | 10/08/19 |
| Nektar Therapeutics (NASDAQ: NKTR ) has seen several setbacks in the near-term, including sagging revenues and a regulatory delay for its investigatio... | |
| Las Vegas Sands Stock Is Rising Because ... | 09/27/19 |
| Las Vegas Sands stock is climbing on Friday, on news that the casino operator will join the S&P 500, replacing Nektar Therapeutics. | |
| Nektar, worst performing stock in S&P 50... | 09/26/19 |
| S&P Dow Jones Indices announced late Thursday it was booting Nektar Therapeutics from the S&P 500 index . Nektar was the worst performing stock on??? | |
| Stocks close mixed as tech shares fall f... | 09/10/19 |
| Stocks whipsawed on Tuesday as tech shares fell for the third straight day. The Technology Select SPDR Fund slid as much 1.6% as Monday's tech sell-of... | |
| Hold rating | 01/06/21 |
| Stifel initiates coverage with Hold rating and announces Price Target of $18.00 | |
| Buy rating | 11/12/20 |
| SVB Leerink maintains Market Perform rating and raises Price Target from $17.00 to $20.00 | |
| Date | 2020-11-05 (AMC) | Est. (EPS/Rev.) | ($0.74)/ 26.33M |
| Actual (EPS/Rev.) | $-0.61/ $30.03 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Silent swinger | hasmat | 41.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
